$XTALPI(02228.HK)SigNature Sciences National Major Science and Technology Project List

I. Basic Project Information

Full Project Name: Mechanism Analysis of Refractory Gastric Cancer and R&D Application of Novel Small Molecule Drug Targets

Project Level: National Major Science and Technology Project for Innovative Drug R&D (formerly "Major New Drug Development") (Highest-level national support in the pharmaceutical field)

Project Initiation Time: 2025 (Project announced in January 2026)

Lead Unit: Peking University Cancer Hospital

Core Participant: SigNature Sciences (Shenzhen) Co., Ltd. (Dr. Zhang Haisheng as project leader)

Other Participants: Nanjing University Gulou Hospital, Fudan University, GenHouse Bio, Xijing Hospital, Air Force Medical University

II. Funding Scale

Central Government Funding: 30-50 million RMB (3-year term, the only national-level project in the gastric cancer field)

Local + Matching Funds: Estimated 10-20 million RMB

Total Funding: 40-70 million RMB

Leverage Effect: Mobilizing 3-5 times social capital, actual R&D investment can reach hundreds of millions of RMB

III. Core Pipeline and Progress

Core Drugs: SIGX1094 (FAK inhibitor, world's first targeted drug for diffuse gastric cancer), SIGX2649 (TEAD inhibitor)

Clinical Stage: Phase I Clinical Trial (led by Professor Shen Lin's team at Peking University Cancer Hospital)

Authoritative Qualifications: China-US IND, FDA Orphan Drug + Fast Track designation, 2025 Galen Prize nomination

Technology Platform: Organoid + AI (World's first drug of this paradigm to enter clinical trials)

IV. Policy Significance (Major Implications)

National Strategic Recognition: Highest-level national R&D project in the pharmaceutical field, signifying national endorsement for AI+Organoid technology

Clinical Unmet Need: No effective targeted drug for diffuse gastric cancer, China accounts for nearly 50% of global cases

Industry Milestone: Incubated by Xtalpi, China's AI-based drug R&D enters the national strategic echelon